The purpose of this study was to determine the role of enteroaggregative Escherichia coli (EAEC) in the development of traveler's diarrhea and the clinical response of patients with EAEC diarrhea following treatment with ciprofloxacin. Sixty-four travelers with diarrhea and no other recognized enteropathogen were enrolled in treatment studies in Jamaica and Mexico from July 1997 to July 1998. EAEC was isolated from 29 travelers (45.3%). There was a significant reduction in the duration of posttreatment diarrhea in the 16 patients treated with ciprofloxacin, as compared with that in the 13 patients who received placebo (mean of 35.3 versus 55.5 hours; P ‫؍‬ .049). There was a nonsignificant reduction in the mean number of unformed stools passed during the 72 hours after enrollment in the ciprofloxacin-treated group (5.6), as compared with that in the placebo group (7.5) (P ‫؍‬ .128). This study provides additional evidence that EAEC should be considered as a cause of antibiotic-responsive traveler's diarrhea.
Escherichia coli associated with diarrhea can be classified in at least six different categories: enterotoxigenic E. coli, enteroinvasive E. coli, enterohemorrhagic or Shigatoxin-producing E. coli, enteropathogenic E. coli, diffusely adherent E. coli, and enteroaggregative E. coli [1] . Of these, the most recently appreciated pathogens are diffusely adherent and enteroaggregative E. coli. These strains are defined by being nonenteropathogenic, showing adherence to HEp-2 cells, and exhibiting a diffuse or aggregative pattern of adherence. In addition, the enteroaggregative E. coli strains do not secrete enterotoxigenic heat-stable or heat-labile toxin [2, 3] .
The role of enteroaggregative E. coli as a cause of diarrhea remains controversial. Volunteer studies have shown conflicting results. Studies of the etiology of diarrhea carried out in Chile, Brazil, India, Spain, and Mexico have provided evidence that enteroaggregative E. coli is associated with diarrhea and appears to be a human pathogen [3] [4] [5] [6] [7] . However, other studies, in Brazil, Mexico, and Thailand, have questioned the pathogenic potential of these strains because they have isolated with similar frequency an enteroaggregative E. coli from patients with diarrhea and asymptomatic controls [8 -10] .
In a post hoc study, we analyzed the frequency of enteroaggregative E. coli as the only isolated enteric organism and examined the clinical response to ciprofloxacin or placebo among travelers with diarrhea in Jamaica and Guadalajara, Mexico, from July 1997 to July 1998.
Materials and Methods
The study population was composed of adults from the United States or Europe who were in Guadalajara, Mexico as students or in Jamaica as tourists. The patients in Guadalajara were enrolled during July 1997 and July 1998. The patients in Jamaica were tourists recruited throughout the year, from July 1997 to July 1998. Subjects participated in two clinical trials conducted in Mexico and Jamaica. In the first, ciprofloxacin was compared with rifaximin, a new antimicrobial from Alfa Wasserman SpA (Bologna, Italy); 190 subjects were enrolled. In the second, provir (Shaman Pharmaceuticals, San Francisco), an antisecretory compound, was examined for antidiarrheal properties in a placebo-controlled clinical trial (164 subjects).
The designs of the two studies, including enrollment criteria and methods of surveillance, were identical. One hundred five people in the two trials had diarrhea without a recognized pathogen in preenrollment stool samples, and their fecal samples were studied for the presence of enteroaggregative E. coli. To examine the effect of antimicrobial therapy on enteroaggregative E. coli diarrhea, we compared the clinical responses in the 64 patients who were randomized to receive either ciprofloxacin in study one (34 subjects from Mexico and 4 from Jamaica) or placebo in study two (6 subjects from Mexico and 20 from Jamaica).
In both studies, diarrhea was defined as the passage of three or more unformed stools during 24 hours, in addition to the presence of one or more clinical indicators of enteric infection (e.g. nausea, vomiting, abdominal cramps or pain, and/or dysentery). Patients were eligible for inclusion if they were men or women 18 years of age or older, enrolled within 72 hours of the onset of illness. Exclusion criteria included active heart, lung, kidney, or intestinal disease; seizure disorder; pregnancy or breast-feeding; administration within 8 hours before enrollment of more than two doses of a symptomatic antidiarrheal compound; and administration within the past week of an antimicrobial agent with expected activity against enteric bacterial pathogens.
If a patient qualified for the study and signed a consent form, an initial clinical evaluation was carried out. In addition, a pretreatment stool specimen was collected and submitted to the field site laboratory for determination of form and other characteristics, such as presence of gross and occult blood, fecal leukocytes, or mucus. Conventional enteric pathogens were sought in preenrollment stool specimens by published methods [11] , and included enterotoxigenic E. coli, Shigella species, Salmonella species, Vibrio species, Campylobacter jejuni/coli, Yersinia enterocolitica, Aeromonas species, Plesiomonas shigelloides, rotavirus, Entamoeba histolytica, Cryptosporidium species, and Giardia lamblia.
If no enteropathogen was found, at least three of five colonies of E. coli from preenrollment stools were analyzed for presence of enteroaggregative E. coli by adherence to cultured HEp-2 cells. We used the method of Cravioto et al. [12] , which was demonstrated to be the optimal procedure in a comparative study by Vial et al. [13] . A chamber slide (Dynatek, Naperville, IL) was seeded with HEp-2 cells that had been grown at 37°C in 5% CO 2 in minimal essential medium (GIBCO-BRL, Gaithersburg, MD) supplemented with 10% fetal calf serum. E. coli strains to be tested were grown overnight at 37°C in tryptic soy broth (BBL Microbiology Systems, Cockeysville, MD) with 1% D-mannose. The cell culture medium in the chamber slide was then replaced with minimal essential medium containing 1% D-mannose without antibiotics, E. coli isolates were added, and the preparation was incubated at 37°C for 3 hours. The slide was washed vigorously three times with PBS, fixed with 100% methanol, and stained with Wright-Giemsa preparation. Positive and negative controls were included in each assay, and all were read in a blinded fashion by two investigators.
All patients included in our study received either ciprofloxacin (500 mg twice daily for 3 days) or placebo (4 times a day for 2 days). Subjects were followed for at least 3 days after enrollment and were required to fill out daily diaries recording number of stools per day, form of stool, and other clinical symptoms.
The parameter that we used to determine the duration of posttreatment illness was the time of the last unformed stool, defined as the time in hours of the last unformed stool passed after the first dose of either therapy or placebo, within the follow-up period of 3 days. All cases in which diarrhea continued after this 72-hour follow-up period or worsened during treatment were considered treatment failures, and the time of the last unformed stool was considered to be 72 hours.
Since the number of samples was small, the statistical analysis was done with use of the two-tailed Wilcoxon's signedrank test. Significance was defined as P Ͻ .05, and a two-tailed test of significance was used.
The studies were approved by the Committee for the Protection of Human Subjects at the University of Texas Health Science Center at Houston.
Results
Among the 38 patients who had received ciprofloxacin and had no identifiable pathogen in stool samples, the pathogens in 16 (42.1%) were identified as enteroaggregative E. coli on the basis of their aggregative adherence to HEp-2 cells. Among the 26 patients who had received a placebo and also had no initially identifiable pathogen, 13 (50.0%) were found to have enteroaggregative E. coli in their stool specimens. The difference in isolation rates (42.1% vs. 50.0%) was not significant. The patients in the two groups had similar demographic and clinical characteristics (age, mean duration of diarrhea at presentation, average number of unformed stools prior to treatment, and other clinical indicators of enteric infection). One difference identified between groups was the distribution of the patients by sex, with more male cases in the placebo group (69.2%) and more females treated with ciprofloxacin (68.7%).
Twenty-six (89.7%) of the 29 patients found to have enteroaggregative E. coli in their stool presented with abdominal pain/cramps, the most common complaint, while 25 (86.2%) had urgency to defecate. Twenty-one (72.4%) experienced excess gas/flatulence and nausea, but only seven (24.1%) reported vomiting. Six (20.7%) had tenesmus, and only one had fever (3.4%), as part of the initial clinical symptoms. Twentyone (72.4%) of the patients presented with watery, nondysenteric diarrhea. Nine (31.0%) were found to have fecal leukocytes, 10 (34.5%) had gross fecal mucus, and 8 (27.6%) had fecal occult blood, including 2 with gross blood in stool.
In addition to the finding of similar clinical presentations in the two groups at the time of enrollment, it was found in our site field laboratory that the stool samples from the ciprofloxacin group more often contained leukocytes (50.0% vs. 7.7%; P ϭ .014) and mucus (50.0% vs. 15.4%; P ϭ .050). There were four treatment failures (one in the ciprofloxacin group and three in the placebo group). These four subjects' diarrhea worsened during day 2 of therapy.
The duration of diarrhea, determined as time to last unformed stool passed in the period of 3 days, was significantly different between the two enteroaggregative E. coli groups. In the group treated with ciprofloxacin, the diarrhea lasted an average of 35.3 hours, ranging from 0 to 58 hours, while the placebo group had diarrhea for an average of 55.5 hours, ranging from 31 to 72 hours (P ϭ .049), a statistically significant difference. The patients treated with ciprofloxacin passed an average of 3.5 stools within the first day of treatment and 5.6 stools in total during the 72 hours after enrollment. Although these numbers are lower than those in the corresponding placebo group (4.6 and 7.5, respectively), these differences were not found to be statistically significant (P ϭ .165 and P ϭ .128) (table 1).
Discussion
Twenty-nine (45.3%) of 64 travelers with diarrhea and no other detectable pathogen in preenrollment stool samples were found to have enteroaggregative E. coli infection. This incidence is higher than the figures found in a previous study, which revealed a prevalence of 30.4% of enteroaggregative E. coli diarrhea among persons traveling from the United States to Mexico in whom no other enteropathogen was recognized [11] . Studies carried out previously by our group in the two study areas of Mexico and Jamaica have shown that enterotoxigenic E. coli is the principal pathogen identified in cases of traveler's diarrhea, found in ϳ20%-40% of cases [11, 14] . The frequency of occurrence of enteroaggregative E. coli in this study is second only to the rate of enterotoxigenic E. coli in the population.
Most patients with enteroaggregative E. coli diarrhea in the analysis presented with watery, nondysenteric diarrhea. About one-third of the patients presented with gross fecal mucus or microscopic fecal leukocytes, and two patients had gross blood in the stool. This is consistent with the majority of previous reports about outbreaks, sporadic cases, and volunteer studies suggesting that enteroaggregative E. coli may cause inflammatory diarrhea [3] [4] [5] [6] [7] [8] [9] . A study of 793 children in Mexico showed that up to one-third of patients with enteroaggregative E. coli diarrhea had grossly bloody stools [10] .
While a common finding in past studies [5, 6] has been the persistence of diarrhea in children infected with enteroaggregative E. coli, we did not follow these subjects sufficiently long to determine whether persistence occurred in our population.
Approximately 50% of cases of traveler's diarrhea are of a definable bacterial etiology, most commonly enterotoxigenic E. coli, Shigella, Salmonella, and Campylobacter species, as well as others such as Vibrio species, Yersinia species, Aeromonas hydrophila, and P. shigelloides, depending on the area in which the patient travels. It is well accepted that antibiotic therapy reduces the total duration of traveler's diarrhea, whether or not a bacterial enteropathogen is found in pretreatment stools [14] . Previous studies done by our group have demonstrated a clinical shortening of duration by antibacterials in diarrhea cases without a definable pathogen [15, 16] and have provided indirect evidence that uncharacterized bacterial pathogens were common causes of traveler's diarrhea.
Evidence from this study suggests that an important number of these undefined cases were of enteroaggregative E. coli diarrhea, because they responded to the antimicrobial ciprofloxacin. Alternatively, these patients may have been infected by other nondetected bacterial pathogens, which could explain their favorable clinical response. In support of our findings, similar results with ciprofloxacin treatment of enteroaggregative E. coli diarrhea in adults with AIDS were described recently by Wanke et al. [17] .
Fluoroquinolones are the current drugs of choice for treatment of moderate to severe traveler's diarrhea because of their safety profile, wide spectrum of coverage, and excellent activity in shortening the disease [14, 15] . Enteroaggregative E. coli are resistant to many antimicrobials; however, these strains appear to be inhibited by fluoroquinolones [18] .
There were three differences in the two treatment groups that need to be considered. First, a majority of placebo-treated subjects were enrolled in Jamaica and of ciprofloxacin-treated patients in Mexico. Second, more males were included in the placebo group and more females in the ciprofloxacin group. Finally, there were more patients with intestinal inflammatory markers in the ciprofloxacin group. We feel that the groups were comparable for the purposes of this analysis. No clinical differences were seen between subjects enrolled in Jamaica vs. Mexico, and sex has not been found to be a factor in the etiology and clinical presentation of traveler's diarrhea [19] .
The conclusion that enteroaggregative E. coli-mediated diarrhea responded to therapy with ciprofloxacin is actually supported by the dissimilarities in the intestinal inflammatory markers seen in the ciprofloxacin-and placebo-treated populations. Since the placebo-treated group had fewer patients with mucus and leukocytes in stools, the bias should be for placebotreated subjects to fare better in comparison with ciprofloxacintreated subjects.
The high frequency of enteroaggregative E. coli in our subjects with no other detected pathogens highlights the importance of enteroaggregative E. coli as a probable cause of traveler's diarrhea. The duration of diarrhea in the group of patients treated with ciprofloxacin was significantly shorter than its duration in the placebo group. The significant reduction in duration of diarrhea in the enteroaggregative E. coli-infected patients who took ciprofloxacin, in comparison with the duration in those who took placebo, further supports the contention that enteroaggregative E. coli is a true pathogen in traveler's diarrhea, rather than a colonizer of gastrointestinal flora.
